prospect
cohort
studi
conduct
august
august
studi
perform
santa
casa
de
misericordia
de
porto
alegr
refer
transplant
center
locat
southern
brazil
patient
includ
exclud
research
base
center
diseas
control
prevent
recommend
patient
studi
present
fever
cough
headach
plu
least
follow
symptom
rhinorrhea
coryza
arthralgia
myalgia
prostrat
sore
throat
chest
pain
abdomin
pain
nasal
congest
individu
exclud
presenc
signssymptom
last
day
inform
written
consent
obtain
patient
studi
approv
local
ethic
committe
respiratori
sampl
obtain
recommend
world
health
organ
briefli
rayon
swab
use
collect
sampl
nasopharyng
oropharyng
site
swab
transport
salin
solut
laboratori
sampl
store
hour
process
total
nucleic
acid
extract
viral
rnadna
mini
kit
life
technolog
grand
island
new
york
usa
store
cdna
influenza
flua
pandem
influenza
influenza
b
flub
rsv
piv
ii
iii
hmpv
synthes
synthesi
supermix
follow
condit
min
min
min
tabl
show
list
primer
use
studi
polymeras
chain
reaction
pcr
assay
perform
use
green
qpcr
pcr
condit
rna
virus
except
rsv
follow
min
min
cycl
follow
min
rsv
condit
min
min
cycl
adv
hbov
detect
convent
pcr
platinum
taq
dna
polymeras
condit
use
amplifi
adv
hbov
min
cycl
determin
durat
viral
shed
patient
posit
pcr
test
retest
everi
day
neg
pcr
test
obtain
patient
chart
review
attempt
obtain
clinic
demograph
inform
compar
distribut
respiratori
virus
infect
overal
popul
transplant
patient
data
patient
posit
pcr
test
respiratori
virus
studi
period
also
review
total
transplant
patient
studi
predominantli
male
median
age
year
rang
year
patient
undergon
kidney
transplant
wherea
other
receiv
liver
lung
stem
cell
transplant
patient
includ
median
time
year
post
transplant
year
total
studi
patient
report
recent
contact
individu
respiratori
symptom
receiv
conjug
influenza
vaccin
main
clinic
manifest
cough
coryza
fever
frequenc
hospit
mean
length
hospit
stay
day
four
patient
die
studi
median
time
death
day
hospit
rang
day
caus
death
patient
dissemin
infect
respiratori
virus
detect
patient
mostli
fall
winter
month
multipl
virus
identifi
individu
includ
patient
virus
detect
preval
viru
piv
iii
follow
rsv
hbov
hmpv
adv
flua
flub
viral
distribut
differ
observ
overal
popul
rsv
predomin
agent
preval
viral
codetect
gener
popul
patient
group
show
concomitantli
respiratori
virus
tabl
present
durat
viral
shed
per
patient
studi
viral
shed
rang
day
hbov
n
day
hmpv
n
averag
durat
viral
shed
day
n
day
piv
iii
n
day
rsv
n
prospect
studi
reveal
transplant
patient
present
acut
respiratori
syndrom
diagnos
viral
infect
total
virus
detect
cohort
patient
found
harbor
viru
detect
multipl
virus
report
brazilian
transplant
patient
recent
studi
report
frequenc
dual
respiratori
viral
infect
children
bronchiol
molecular
assay
ad
diagnost
list
clinic
laboratori
therefor
use
modern
sensit
method
pcr
diagnosi
respiratori
tract
infect
even
higher
rate
viral
codetect
anticip
found
transplant
set
shown
detect
multipl
respiratori
virus
transplant
recipi
associ
poor
prognosi
patient
studi
piv
iii
frequent
viru
detect
transplant
patient
follow
rsv
hbov
hmpv
adv
previou
investig
use
convent
diagnost
method
ie
direct
immunofluoresc
viral
cultur
incid
piv
iii
infect
follow
transplant
vari
hand
studi
base
pcr
reveal
higher
frequenc
piv
iii
infect
high
contrast
transplant
patient
piv
iii
predomin
viru
rsv
main
caus
respiratori
infect
popul
refer
hospit
high
rsv
frequenc
detect
patient
suggest
patient
probabl
children
accord
literatur
suggest
rsv
one
common
caus
sever
lower
respiratori
diseas
young
children
human
rhinovirus
coronavirus
frequent
associ
common
cold
gener
consid
replic
princip
within
upper
respiratori
tract
despit
high
frequenc
virus
popul
real
import
agent
transplant
popul
remain
determin
studi
hbov
hmpv
adv
flua
flub
detect
transplant
patient
respect
frequenc
agreement
literatur
data
contrast
detect
transplant
patient
low
percentag
detect
studi
may
justifi
massiv
immun
campaign
occur
brazil
month
studi
initi
inform
durat
viral
shed
import
establish
effect
infect
control
measur
hospit
environ
work
report
prolong
shed
cohort
transplant
patient
individu
excret
virus
day
find
agreement
literatur
prolong
shed
report
piv
iii
day
rsv
day
hmpv
day
infect
even
though
previou
studi
show
prolong
hbov
shed
children
patient
hbov
infect
includ
studi
therefor
abl
properli
evalu
hbov
shed
transplant
cohort
current
data
shed
agreement
previou
report
suggest
presenc
signific
risk
factor
prolong
viral
shed
median
day
limit
work
includ
inabl
test
rhinoviru
cohort
patient
difficulti
follow
individu
prolong
period
time
anoth
limit
small
number
transplant
patient
studi
includ
patient
present
acut
respiratori
ill
symptom
last
day
base
cdc
recommend
viral
shed
prolong
patient
demonstr
current
studi
criterion
could
reduc
number
patient
enrol
studi
furthermor
alreadi
known
transplant
patient
fewer
milder
symptom
fact
could
miss
patient
mild
symptom
could
affect
estim
durat
shed
work
demonstr
respiratori
virus
signific
caus
morbid
transplant
patient
use
molecular
tool
clinic
practic
may
facilit
manag
patient
particularli
infect
control
measur
consid
transplant
patient
demonstr
prolong
viral
shed
clinic
relev
potenti
intrahospit
dissemin
diseas
remain
determin
